US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its ... system and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) devices were able to reduce ...

Boston Scientific Corp. reported positive data for two key ... Additionally, a sub-analysis of the OPTION trial demonstrated that the Watchman FLX device significantly reduced bleeding outcomes ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...

One of the standout products in Boston Scientific's portfolio is the Watchman FLX Left Atrial Appendage Closure (LAAC) device. Recent clinical trial results from the OPTION study demonstrated the ...

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025. Boston Scientific Corporation (NYSE ...

Boston Scientific projected full-year revenue growth between 12.5% and 14.5%, compared with the prior year. The company's key growth drivers include its stroke prevention device, Watchman ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...